CBE ID
3725
Endorsed
Endorsement Status
1.1 New or Maintenance
E&M Cycle
Is Under Review
No
Next Planned Maintenance Review
Fall 2027
1.3 Measure Description
Percent of all new home dialysis patients in the measurement year for whom >=90 consecutive days of home dialysis was achieved.
-
-
1.5 Measure Type
-
1.14 Numerator
Patients from the denominator who achieved >=90 consecutive days of home dialysis in the measurement year.
-
1.15 Denominator
The total number of eligible new home dialysis patients attributed to the dialysis facility during the measurement year.
-
1.13a Data dictionary not attachedNoOLD 1.12 MAT output not attachedAttached
-
Most Recent Endorsement ActivityNot Endorsed Renal Fall 2022Initial EndorsementLast Updated
-
StewardSteward Organization EmailMeasure Developer Secondary Point Of Contact
United States
-
-
-
Risk adjustment approachOffRisk adjustment approachOffConceptual model for risk adjustmentOffConceptual model for risk adjustmentOff
-
Effective March 27, 2023, the National Quality Forum (NQF) is no longer the consensus-based entity (CBE) funded through the Centers for Medicare & Medicaid Services (CMS) National Consensus Development and Strategic Planning for Health Care Quality Measurement Contract. Battelle has been selected to oversee the endorsement & maintenance (E&M) of clinical quality and cost/resource use measures. Since the Fall 2022 cycle launched at NQF, measures submitted to this E&M cycle continued along the prior E&M protocols that were in place at time of the Fall 2022 “Intent to Submit.” Battelle took over the E&M work for the Fall 2022 cycle after developers and/or stewards submitted their full measure information to NQF, which for CBE #3725, the most recent measure specifications can be found here: https://p4qm.org/sites/default/files/2024-02/3725.zip
Battelle took over the E&M work beginning with the public comment period to close the E&M committees for the post-comment meeting, convening the CSAC to render a final endorsement decision, and executing the appeals period.